Navigation Links
GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
Date:9/1/2011

ATLANTA, Sept. 1, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced the increase of an existing $3.6 million annual award to $4.4 million for its Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Grant supporting GeoVax's HIV/AIDS vaccine program.

This five-year grant was originally awarded in 2007 to GeoVax by the National Institutes of Health-National Institute of Allergy & Infectious Disease (NIH-NIAID), an agency of the U.S. government. The increase reflects an administrative supplement to support vaccine response characterization. Only highly successful IPCAVD grants receive supplements, which allow these successful programs to move more rapidly. This most recent supplement for the 2011-12 grant year is the third for the GeoVax program, bringing the initial award of $15.4 million now to an aggregate award of $20.4 million.

Harriet Robinson, Ph.D., GeoVax's Chief Scientific Officer, stated, "This award is important for the advancement of our GM-CSF adjuvanted vaccine that is achieving unprecedented levels of prevention of infection. When we started this project, I thought we could only control, not prevent, infections. It is truly wonderful to be achieving high levels of prevention of infection, and we are working very hard to move the vaccine through the needed efficacy trials for human use."

About GeoVax

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and involves 300 participants at sites in the United States and South America. Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit www.geovax.com.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.  GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so.  More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

Contact:

The Investor Relations Group
Erika Moran, Investor Relations
Janet Vasquez, Public Relations
(212) 825-3210


'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GeoVax Labs, Inc. Announces Second Quarter Financial Results
2. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
3. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
4. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
5. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
6. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
7. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
8. GeoVax Labs Engages The Investor Relations Group
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year End 2009 Financial Results
10. GeoVax Labs, Inc. Plans Public Offering
11. GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... 8, 2017  StatLab Medical Products ("StatLab" ... manufacturer of diagnostic supplies for the anatomic ... & Company LP ("Cressey & Company"), a ... growth-focused investment in the Company. Cressey & ... from selling shareholder, Prairie Capital, L.P., with ...
(Date:6/5/2017)... June 5, 2017 Kohll,s Pharmacy & Homecare is the ... the United States . The Raizer is a simple ... person up to an almost-standing position within a ... by one assistant and does not require any ... that a child can operate it, and lightweight ...
(Date:5/30/2017)... CHICAGO , May 30, 2017 Hill-Rom Holdings, ... th Annual Global Healthcare Conference on Tuesday, June 13, ... John Greisch , Hill-Rom,s president and chief executive officer, ... The live audio webcast can be accessed at ... after conclusion of the live event through September 13, 2017. ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... ... Today, June 27th is PTSD Awareness Day. Over half a million U.S. ... care due to lack of effective treatments, fear of stigma or insufficient government resources. ... veterans are at an increased risk for self-destructive behavior, including alcohol/drug abuse, depression, anxiety ...
(Date:6/27/2017)... ... , ... Children’s National Health System received top honors in the 2017-18 U.S ... out of more than 1500 neonatal intensive care units coast to coast. ... given to the top performing children’s hospitals in the country. , In addition ...
(Date:6/26/2017)... ... 26, 2017 , ... Dr. Martin Bastuba, MD, FACS, founder ... the Fertility Center of California, is pleased to announce the addition of two ... TESA (percutaneous testicular sperm extraction). These minimally invasive treatments are primarily used to ...
(Date:6/26/2017)... New Mexico (PRWEB) , ... June 26, 2017 ... ... dysfunction, anorgasmia, and urinary leakage is revolutionizing the way women look and feel ... is tackling the problem of female sexual dysfunction and urinary leakage head on ...
(Date:6/26/2017)... RU (PRWEB) , ... June 26, 2017 , ... ... released a whitepaper that pledges to solve many catastrophic issues within funding campaigns. ... 2017. , The typical notion of crowdfunding - the raising of funds through the ...
Breaking Medicine News(10 mins):